Orteronel 300mg BID
GETHI 2013-01
Phase 2 small_molecule terminated
Quick answer
Orteronel 300mg BID for Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated